Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

lurtotecan liposome

Known as: liposomal lurtotecan, liposome, lurtotecan 
A liposome-encapsulated formulation of lurtotecan with antineoplastic activity. Lurtotecan, a semisynthetic analogue of camptothecin, selectively… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
PURPOSE Liposomal lurtotecan (OSI-211) is a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan… 
2005
2005
5017 Background: OSI-211 is a liposomal formulation of lurtotecan, a topoisomerase-I inhibitor. In a previous randomised dose… 
2005
2005
2074 Background: OSI-211 is a topoisomerase (topo) I inhibitor in liposomal formulation. In vivo efficacy of the liposomal… 
Highly Cited
2004
Highly Cited
2004
OBJECTIVES To determine the safety and efficacy of a novel topoisomerase I inhibitor, liposomal lurtotecan, in patients with… 
2004
2004
The purpose of this study was to evaluate the activity and safety of OSI-211, the liposomal form of lurtotecan, in patients… 
2004
2004
Purpose: To define the maximum tolerated dose (MTD), recommended phase II dose (RD) and dose limiting toxicity (DLT) of liposomal… 
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2003
2003
OSI-211 (liposomal lurtotecan), was evaluated using several different dose schedules (1mg/kg, d1-5, 1.75 mg/kg d1, 3, 5 and 6 mg… 
2001
2001
Prolonging tumor exposure to topoisomerase I inhibitors has been correlated to enhance the efficacy of those agents. Lurtotecan…